Communicate with Supplier? Supplier
Amy Cheng Ms. Amy Cheng
What can I do for you?
Chat Now Contact Supplier
Taizhou Volsen Chemical Co., Ltd.
About Us
Taizhou Volsen Chemical Co., Ltd. is professional in R&D, producing and marketing Pharmaceutical Raw Materials, Pharmaceutical Intermediates in China. VOLSEN consists of about 100 experienced employees including 3 PhD and 10 Master, and 35000 sqm facilities including research laboratories, kilo lab, pilot plant and full manufacturing plant, VOLSEN R&D specialists, quality manager and sales with abundance experience make sure products are reliable and service is professional. The producing person inspect every step of the whole process and check up the quality strictly, in order to insure every batch of raw material achieve the standard of EP,CP, JP,BP etc.Matching to the diversified requirements of companies VOLSEN is steadily marching to reach the peaks. Volsen owns a professional custom synthesis department, with more than 15 senior scientific research chemical personnels who have a graduate degree or above. We also have an independent scientific management system. Our company integrates years of production experiences and talent reserves that forms a strong R&D production capacity, furthermore we could undertake various chemicals customizations from kg to ton relying on the existing production base and equipment. Manufacturing Unit is equipped with a facility of progressive reeducation of emissions, effluents and discharge of waste material that are known to have a negative impact on the environment. Besides, Laboratory as well as plant is equipped with latest Machinery, Equipments, Technical personnel & Means of communications. Due to supply of reliable quality, efficient follow up, scheduled delivery and prompt response to any matter, company wins good comments from customers. We aimed at delivering real business value to our clients. For any interest, pls call on us or email us to get our best services.
View more Visit My Factory
Company Equipment
Product Center
Active Pharmaceutical IngredientsPharmaceutical IntermediatesContract ManufacturingR&D PharmaceuticalFood additives
Latest News

Focus on the latest news of the company and industry, and keep abreast of the latest developments

  • Pfizer: CDK4/6 new drug palbociclib First in class, will break $5 billion this year Recently, Pfizer released its Q3 financial report for 2019 and disclosed its results for the first three quarters.Pfizer Q3's global performance was 12.68 billion US dollars; the first three quarters of the performance was 39.062 billion US dollars. Pfizer Biopharmaceuticals Group (PBG) - Pfizer Biopharmaceuticals (including innovative drugs, biosimilars, hospitals focused on anti-infectives and sterile injectables), with a performance of $28.887 billion in the first three quarters of 2019.The mature pharmaceutical business unit (composed of patent expired brand drugs and generic drugs) is Upjohn, with a performance of $8.077 billion in the first three quarters of 2019. The consumer health sector's results for the first three quarters of 2019 were $2.098 billion. Pfizer's global product performance in the first three quarters of 2019 Ibrance, the world's first CDK4/6 inhibitor, has a global revenue of $3.677 billion.27% year-on-year growth;The product is expected to exceed the $5 billion mark in FY 2019. It was first approved in the United States in February 2015. After more than four years, it became a super blockbuster. The world's first cyclin-dependent kinase (CDK) 4/6 inhibitor, IBRANCE® ( palbociclib) was approved by the Chinese National Drug Administration (NMPA) on July 31, 2018. IBRANCE® for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, should be combined with aromatase inhibitors as postmenopausal women Initial endocrine therapy. Peirnar 13 vaccine (Prevnar 13) first quarter results of 4.268 billion US dollars Xeljanz (Tofacitinib) had a previous quarterly performance of $1.634 billion. (There are already two generic drugs approved for listing in China, Qi
  • On November 8,Jiangsu Hengrui Pharmaceutical Co., Ltd. announced that it has recently received the "Clinical Trial Notice" approved by the State Drug Administration. The drug Hengrui Medicine is the application for declaration and production, and the National Bureau finally approved the clinical trial. It seems that it is necessary to continue to do clinical trial follow-up production. 1. Name of the drug:Intravenous inhalation powder for Indacaterol Maleate Dosage form: inhalation powder Specification: 150μg (calculated according to C24H28N2O3) Application: Declaration of production Applicant: Jiangsu Hengrui Pharmaceutical Co., Ltd. Reception number: CYHS1900067 2. Other conditions of the drug Indacaterol Maleate inhalation powder is a novel long-acting β2-receptor agonist intended for maintenance therapy in adults with chronic obstructive pulmonary disease (COPD).Inhaled Powder Indacaterol Maleate was first approved by Novartis Pharmaceuticals in November 2009,Specifications are 150μg and 300μg.In July 2011, it was approved by the US FDA and Japan PMDA, and the approved specifications were 75μg and 150μg respectively. Up to now, this product has been approved for listing in more than 50 countries around the world.Upon enquiry, in June 2012, Novartis's inhaled powder of Indacaterol Maleate was approved for import in China. The product name is Anrun, and the specification is 150μg.In January 2019, the company's first inhaled powder of Indacaterol M
  • New medicine for peripheral neuralgia! The first three totals of Tarlige (mirogabalin) were approved for the treatment of peripheral neuropathic pain (PNP) January 17, 2019 / Bio Valley BIOON / -- Daiichi Sankyo, the Japanese pharmaceutical company, recently announced that Tarlige (mirogabalin besylate) 2.5mg, 5mg, 10mg, 15mg tablets have been approved in Japan for the treatment of peripheral neuropathic pain (PNP).In general, an adult patient's initial dose is 5 mg, taken orally twice a day, and then gradually increased by 5 mg to 15 mg at intervals of at least one week The dose can be appropriately adjusted between 10 mg and 15 mg depending on the age and symptoms, and taken orally twice a day for one week. The active pharmaceutical ingredient of Tarlige is mirogabalin, an α2δ ligand created by the first three,By oral administration, the α2δ-1 subunit of voltage-dependent calcium channels (1 and 2) can be preferentially and selectively bound, but the potency is significantly higher than that of pregabalinThese calcium channels are widely present in the nervous system that mediates pain transmission and management in various regions of the body. mirogabalin has unique binding properties and long-acting effects.Mirogabalin belongs to the class of drugs called gabapentinoid, which is the same as gabapentin and pregabalin. The first three submitted a new drug application for Tarlige in February 2018.The drug was approved based on a phase III clinical study in patients with diabetic peripheral neuropathic pain (DPNP) and positive data from a phase III clinical study in patients with postherpetic neuralgia (PHN).Both studies were conducted in Asia, including Japan. In the first three, Tarlige is expected to provide Japanese patients and healthcare professionals with an innovative treatment for peripheral neuropathic pain (PNP).PNP is caused by peripheral nerve damage or dysfunction caused by various causes. Typical PNPs include di
Featured Products



Recommend our products for you, so that you can quickly preview the products.

View more
  • Histone Deacetylase Inhibitor Givinostat(Gavinostat)CAS 497833-27-9
  • Benzyl (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)pyrrolidine-1-carboxylate 2095311-51-4
  • Tert-Butyl (5-Tosyl-5H-Pyrrolo [2,3-B]Pyrazin-2-Yl)Carbamate For Upadacitinib  CAS 1201187-44-1
  • 4-(5-(4-(Pentyloxy)phenyl)Isoxazol-3-yl)Benzoic Acid For Micafungin  Cas 179162-55-1
  • Finafloxacin Intermediate CAS 117528-64-0
  • 2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole For  Omarigliptin 1280210-80-1
  • Synthesis Process Of Omarigliptin Intermediate CAS  951127-25-6
  • (3R,4R)-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine Used to Make Alvimopan 119193-19-0
  • Alvimopan Phenylpropanoic Acid Methyl Ester Hydrochloride 170098-28-9